| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
10 |
/ |
2020 |
|
|
|
| |
Data sporządzenia: |
2020-04-09 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
Milestone Scientic, the Licensor of Milestone Medical Inc. Announces Pricing of Above
Market $4.5 Million Public Offering of Common Stock and Warrants
|
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, “the Company", “the Issuer"_,
today announced that Milestone Scientific, Inc. _NYSE:MLSS, "Milestone Scientific"_,
the licensor of the Company’s computer-controlled injection and drug delivery technology
as well as the majority shareholder of the Issuer, intends to offer for sale a combination
of shares of Milestone Scientific’s common stock and warrants to purchase shares of
its common stock in an underwritten public offering. Milestone Scientific intends
to advance the proceeds from this offering to the Issuer for manufacturing, marketing,
sales and distribution of its CompluFlo® Epidural System and development of new products
and new product uses, working capital and general corporate purposes. The offering
is subject to market conditions, and there can be no assurance as to whether the net
or when the offering may be completed, or as to the actual size or terms of the offering.
The Board of Directors of the Issuer also announced the pricing of an underwritten
offering of 4,750,000 shares of Milestone Scientific’s common stock and warrants to
purchase up to an aggregate of 2,375,000 shares of the its common stock. Each share
of common stock is being sold together with a warrant to purchase 0.50 of one share
of common stock at a combined price to the public of $0.95. Gross proceeds before
underwriting discounts and commissions and estimated offering expenses, are expected
to be approximately $4.5 million.
The warrants will be immediately exercisable at a price of $1.20 per share of common
stock and will expire three years from the date of issuance. The shares of common
stock and the accompanying warrants can only be purchased together in the offering
but will be issued separately and will be immediately separable upon issuance. The
offering is expected to close on or about April 14, 2020, subject to customary closing
conditions.
Maxim Group LLC is acting as sole book-running manager for the offering.
Milestone Scientific also has granted to the underwriter a 45-day option to purchase
up to an additional 712,500 shares of common stock and/or warrants to purchase up
to 356,250 shares of common stock, at the public offering price less discounts and
commissions.
The securities described above are being offered by Milestone Scientific pursuant
to a registration statement previously filed and declared effective by the Securities
and Exchange Commission _SEC_. The securities are being offered by means of a prospectus
supplement and accompanying prospectus, forming part of the registration statement.
A preliminary prospectus supplement and accompanying prospectus relating to this offering
have been filed with the SEC. Electronic copies of the preliminary prospectus supplement
and the accompanying prospectus relating to this offering may be obtained from Maxim
Group LLC. Electronic copies of the preliminary prospectus supplement and accompanying
prospectus are also available on the website of the SEC.
|
|
|
RB_ASO: Milestone Scientic, the Licensor of Milestone Medical Inc. Announces Pricing of Above
Market $4.5 Million Public Offering of Common Stock and Warrants 
